Sign in to view content

Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy Phase 3 PULSAR Trial Subgroup Analysis

David T.W. Wong, MD, FRCS(C), FASRS

Video
Published 2023

Related

RGX-314 for Neovascular AMD: Ongoing Phase I/IIa Results for Cohorts 1-5
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2020
12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial
Rishi P. Singh, MD
Updates from the Field
2022
High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more